|作者：||Duan Feng, Bai Yan-Hua, Cui Li, Li Xiao-Hui, Yan Jie-Yu, Wang Mao-Qiang|
1Department of Interventional Radiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
2Department of Interventional Radiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China. firstname.lastname@example.org.
|刊名：||World journal of gastrointestinal oncology, 2020, Vol.12 (1), pp.92-100|
|关键词：||Chemoembolization; Hepatocellular carcinoma; Radiofrequency ablation; Simultaneous treatment; Transcatheter arterial chemoembolization;|
|原始语种摘要：||BACKGROUND(#br)Hepatocellular carcinoma (HCC) is a common cancer and a leading cause of tumor-related death. Patients with large HCC (≥ 8 cm) are at an advanced stage and have poor prognosis, and hepatic resection may not be suitable, and the incidence of postoperative recurrence is high.(#br)AIM(#br)To evaluate recurrence and mid-term survival of patients with large HCC treated by transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA).(#br)METHODS(#br)This was a retrospective study. From 2010 to 2013, 46 consecutive patients with large HCC were treated with simultaneous TACE and RFA. Thirty-five of 46 patients had a single tumor. Progression-free survival (PFS) and overall survival (OS) were analyzed at 2 years and 3 years,... respectively.(#br)RESULTS(#br)Forty-six patients treated by simultaneous TACE and RFA had no significant complications and treatment was successful. After 3 years, median PFS and OS were 10.21 ± 1.58 mo and 26.44 ± 2.26 mo, retrospectively. The survival rate was 67.5% after 2 years and 55.67% after 3 years.(#br)CONCLUSION(#br)These preliminary data show that simultaneous TACE and RFA are safe and effective for large HCC.|